Graduate Studies Clause Samples

The Graduate Studies clause outlines the terms and conditions governing a student's participation in a graduate-level academic program. It typically specifies requirements such as enrollment status, academic performance standards, and obligations related to research or coursework. By clearly defining these expectations, the clause ensures both the institution and the student understand their respective responsibilities, thereby promoting academic progress and minimizing misunderstandings.
Graduate Studies. This benefit does not apply to Graduate Studies courses.
View SourceView Similar (8)
Graduate Studies. A listing of the program of graduate studies.
View SourceView Similar (2)
Graduate Studies. The U of A's flourishing research programs indicate a commitment to scholarship, pursuit of knowledge, and the application of that knowledge to the solution of contemporary problems. There are graduate programs in many fields of engineering leading to the degrees of Master of Science (MSc), Master of Engineering (MEng), and Doctor of Philosophy (PhD). A combined Master of Business Administration/Master of Engineering (MBA/MEng) degree program is also available. For more information on Graduate Studies, contact the individual Engineering departments.
View Source
Graduate Studies. The members shall be eligible to receive reimbursement of tuition cost for courses taken in a college or university pursuant to the following provisions: A. Courses must be approved in advance by the Superintendent and must be related to the administrative or supervisory position held by the member. B. Courses to be approved shall be those not required for full certification for the position held by the member. C. Members with tenure status shall be eligible for reimbursement for up to twelve (12) credits of study for each fiscal year. D. Non-tenured members shall be eligible for reimbursement for up to nine (9) credits of study each fiscal year, but only after one (1) year of satisfactory service in the school district. E. Reimbursement will be made for any amount up to the current tuition rate charged for courses taken at the Rutgers University Graduate School of Education. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇▇ will be made when a member submits a receipt (or copy) of tuition paid and a copy of course credit issued by the college or university.
View Source
Graduate Studies. 12.1 Administrators shall receive reimbursement for the full cost of tuition for all courses of graduate study previously approved by the Superintendent as of November 24, 2008 and successfully completed with a grade of “B” or better, in an amount not to exceed 9 credits in any fiscal school year. Administrators shall receive reimbursement at the tuition rate in effect for graduate study at the State University of New York for all courses of graduate study approved by the Superintendent after November 24, 2008 and successfully completed with a grade of “B” or better, in an amount not to exceed 9 credits in any fiscal school year. However, administrators who are in the bargaining unit and who are matriculated in a doctoral program as of November 24, 2008 shall receive reimbursement for the full cost of tuition for all courses of graduate study in such program approved by the Superintendent after November 24, 2008 if such courses are successfully completed by June 30, 2010 with a grade of “B” or better.
View Source
Graduate Studies 
View Source

Related to Graduate Studies

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in ▇▇▇▇ rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.